Optimal Use of FOLFOXIRI Plus Bevacizumab as First-Line Systemic Treatment in Metastatic Colorectal Cancer

被引：1

作者：

Khatib, Jude ^{[1
]}

Kainthla, Radhika ^{[1
]}

机构：

[1] Univ Texas Southwestern Med Ctr Dallas, Dept Hematol & Oncol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA

来源：

CURRENT COLORECTAL CANCER REPORTS | 2020年 / 16卷 / 04期

关键词：

FOLFOXIRI; Bevacizumab; Metastatic colorectal cancer; Conversion therapy; First-line therapy; RANDOMIZED-TRIAL; OPEN-LABEL; RESECTION; CHEMOTHERAPY; MANAGEMENT; CONSENSUS; SURVIVAL; PHASE-3;

D O I：

10.1007/s11888-020-00455-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose of Review Colorectal cancer is the second leading cause of cancer-related deaths in the USA with more than half of diagnosed patients developing metastatic disease. The mainstay of treatment for metastatic disease is chemotherapy, and upfront treatment has generally consisted of a two-drug chemotherapy combination (FOLFOX or FOLFIRI) plus a biologic agent. In this review, we explore the emerging role of the three-drug chemotherapy combination FOLFOXIRI plus bevacizumab as first-line treatment in metastatic colorectal cancer. Recent Findings Randomized trials evaluating the efficacy of FOLFOXIRI plus bevacizumab have shown improvement in objective response rate, overall survival, and resection rate when compared to previous standard therapy. However, this comes with added toxicity, which can be one of the main barriers to its widespread implementation. FOLFOXIRI plus bevacizumab is an effective therapy in carefully selected patients; however, more clinical trials investigating the regimen's role in colorectal cancer remain a significant need.

引用

页码：89 / 95

页数：7

共 21 条

[1]

Benson A.I., 2020, J NATL COMPR CANC NE

[2] Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial [J].

Cremolini, Chiara ;

Antoniotti, Carlotta ;

Rossini, Daniele ;

Lonardi, Sara ;

Loupakis, Fotios ;

Pietrantonio, Filippo ;

Bordonaro, Roberto ;

Latiano, Tiziana Pia ;

Tamburini, Emiliano ;

Santini, Daniele ;

Passardi, Alessandro ;

Marmorino, Federica ;

Grande, Roberta ;

Aprile, Giuseppe ;

Zaniboni, Alberto ;

Murgioni, Sabina ;

Granetto, Cristina ;

Buonadonna, Angela ;

Moretto, Roberto ;

Corallo, Salvatore ;

Cordio, Stefano ;

Antonuzzo, Lorenzo ;

Tomasello, Gianluca ;

Masi, Gianluca ;

Ronzoni, Monica ;

Di Donato, Samantha ;

Carlomagno, Chiara ;

Clavarezza, Matteo ;

Ritorto, Giuliana ;

Mambrini, Andrea ;

Roselli, Mario ;

Cupini, Samanta ;

Mammoliti, Serafina ;

Fenocchio, Elisabetta ;

Corgna, Enrichetta ;

Zagonel, Vittorina ;

Fontanini, Gabriella ;

Ugolini, Clara ;

Boni, Luca ;

Falcone, Alfredo .

LANCET ONCOLOGY, 2020, 21 (04) :497-507

[3] FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study [J].

Cremolini, Chiara ;

Loupakis, Fotios ;

Antoniotti, Carlotta ;

Lupi, Cristiana ;

Sensi, Elisa ;

Lonardi, Sara ;

Mezi, Silvia ;

Tomasello, Gianluca ;

Ronzoni, Monica ;

Zaniboni, Alberto ;

Tonini, Giuseppe ;

Carlomagno, Chiara ;

Allegrini, Giacomo ;

Chiara, Silvana ;

D'Amico, Mauro ;

Granetto, Cristina ;

Cazzaniga, Marina ;

Boni, Luca ;

Fontanini, Gabriella ;

Falcone, Alfredo .

LANCET ONCOLOGY, 2015, 16 (13) :1306-1315

[4] Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial [J].

Gruenberger, T. ;

Bridgewater, J. ;

Chau, I. ;

Garcia Alfonso, P. ;

Rivoire, M. ;

Mudan, S. ;

Lasserre, S. ;

Hermann, F. ;

Waterkamp, D. ;

Adam, R. .

ANNALS OF ONCOLOGY, 2015, 26 (04) :702-708

[5] Randomized trial of simplified LV5FU2 versus FOLFOX7 followed by FOLFIRI (MIROX) in patients with initially resectable metastatic colorectal cancer: a GERCOR study [J].

Hebbar, Mohamed ;

Chibaudel, Benoist ;

Andre, Thierry ;

Louvet, Christophe ;

Smith, Denis ;

Mineur, Laurent ;

Bennamoun, Mostepha ;

Mabro, May ;

Brusquant, David ;

Bonnetain, Franck ;

Pruvot, Francois-Rene ;

de Gramont, Aimery .

JOURNAL OF CHEMOTHERAPY, 2013, 25 (02) :104-111

[6] Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM) [J].

Hurwitz, Herbert, I ;

Tan, Benjamin R. ;

Reeves, James A. ;

Xiong, Henry ;

Somer, Brad ;

Lenz, HeinzJosef ;

Hochster, Howard S. ;

Scappaticci, Frank ;

Palma, John F. ;

Price, Richard ;

Lee, John J. ;

Nicholas, Alan ;

Sommer, Nicolas ;

Bendell, Johanna .

ONCOLOGIST, 2019, 24 (07) :921-932

[7] Perioperative chemotherapy for resectable colorectal liver metastases: Where now? [J].

Jones, R. P. ;

Malik, H. Z. ;

Fenwick, S. W. ;

Poston, G. J. .

EJSO, 2013, 39 (08) :807-811

[8] Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy [J].

Kopetz, Scott ;

Chang, George J. ;

Overman, Michael J. ;

Eng, Cathy ;

Sargent, Daniel J. ;

Larson, David W. ;

Grothey, Axel ;

Vauthey, Jean-Nicolas ;

Nagorney, David M. ;

McWilliams, Robert R. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (22) :3677-3683

[9] Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival [J].

Lee, Won-Suk ;

Yun, Seong Hyeon ;

Chun, Ho-Kyung ;

Lee, Woo-Yong ;

Yun, Hae-Ran ;

Kim, Jhingook ;

Kim, Kwhanmien ;

Shim, Young Mog .

INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2007, 22 (06) :699-704

[10]

Loupakis F, 2015, CANCER, V11, P293, DOI [10.1007/s11523-015-0400-y, DOI 10.1007/S11523-015-0400-Y]

← 1 2 3 →